Mangalam Drugs and Organics Limited secured a significant repeat export order worth approximately ₹15 crore from a reputed international client for its anti-malarial API. This underlines the company’s global reputation in pharma exports and its strategic push to advance India’s API market leadership.
Mangalam Drugs and Organics Limited , a prominent Indian pharmaceutical player, has disclosed receipt of a repeat export order totalling ₹15 crore for anti-malarial active pharmaceutical ingredients (API) from a respected global customer. The announcement comes under SEBI’s Listing Obligations and Disclosure Requirements regulations as a material event, signaling strengthened commercial relationships and ongoing international demand for Mangalam’s API product line.
This repeat order affirms the company’s reliability and quality standards in pharmaceutical exports, especially for life-saving anti-malarial compounds that contribute to global health initiatives. The export order’s substantial value supports Mangalam Drugs’ growth strategy, enhancing its position as a preferred API supplier in the international market.
Key Highlights:
-
Company: Mangalam Drugs and Organics Limited
-
Order type: Repeat export order for anti-malarial API
-
Client: Reputed international customer
-
Value: Approx. ₹15 Crore
-
Regulatory disclosure: As per SEBI’s Listing Obligations and Disclosure Requirements
-
Strategic impact: Boosts India’s API export footprint; affirms international quality standards
Sources: Regulatory filing - Mangalam Drugs and Organics Limited BSE/NSE announcement.